BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

999 related articles for article (PubMed ID: 10232600)

  • 41. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
    Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
    Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
    Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cotransfected sodium iodide symporter and human tyroperoxidase genes following human telomerase reverse transcriptase promoter for targeted radioiodine therapy of malignant glioma cells.
    Li W; Tan J; Wang P; Wu P
    Cancer Biother Radiopharm; 2011 Aug; 26(4):443-51. PubMed ID: 21797672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy.
    Nakamoto Y; Saga T; Misaki T; Kobayashi H; Sato N; Ishimori T; Kosugi S; Sakahara H; Konishi J
    J Nucl Med; 2000 Nov; 41(11):1898-904. PubMed ID: 11079502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.
    Schmutzler C; Winzer R; Meissner-Weigl J; Köhrle J
    Biochem Biophys Res Commun; 1997 Nov; 240(3):832-8. PubMed ID: 9398654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interleukin-4 in patients with prostate cancer.
    Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
    Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells.
    Horii K; Suzuki Y; Kondo Y; Akimoto M; Nishimura T; Yamabe Y; Sakaue M; Sano T; Kitagawa T; Himeno S; Imura N; Hara S
    Mol Cancer Res; 2007 Apr; 5(4):383-91. PubMed ID: 17426252
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
    Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
    Wang LG; Ossowski L; Ferrari AC
    Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
    Willhauck MJ; Sharif Samani BR; Klutz K; Cengic N; Wolf I; Mohr L; Geissler M; Senekowitsch-Schmidtke R; Göke B; Morris JC; Spitzweg C
    Gene Ther; 2008 Feb; 15(3):214-23. PubMed ID: 17989705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effect of PC-1 gene expression on migration ability of prostate cancer cells].
    Zhang H; Wan LC; Wang J; Zhou JG; Huang CF
    Ai Zheng; 2005 Sep; 24(9):1043-7. PubMed ID: 16159422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
    Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
    Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
    Paliouras M; Diamandis EP
    Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME; Sato N; Sadar M; Yago V; Bruchovsky N; Sullivan L
    J Cell Biochem; 1998 Jun; 69(3):271-81. PubMed ID: 9581866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
    Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
    Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Inhibition of the expression of prostate specific antigen by curcumin].
    Yang L; Zhang LY; Chen WW; Kong F; Zhang PJ; Hu XY; Zhang JY; Cui FA
    Yao Xue Xue Bao; 2005 Sep; 40(9):800-3. PubMed ID: 16342680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma.
    Ma XJ; Huang R; Kuang AR
    Cancer Invest; 2009 Jul; 27(6):673-81. PubMed ID: 19241193
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen.
    Miyake H; Hara I; Gleave ME; Eto H
    Prostate; 2004 Dec; 61(4):318-23. PubMed ID: 15389725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer.
    Lee CH; Liu M; Sie KL; Lee MS
    Anticancer Res; 1996; 16(4A):1805-11. PubMed ID: 8712704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.